β
Outcome MeasureMystical Experience

EBI

Emotional Breakthrough Inventory

2 Papers in Blossom

Clinical Thresholds

630
Low breakthrough
Score 6–14
Moderate breakthrough
Score 15–22
High breakthrough
Score 23–30

Outcome Data Across Studies

Reported results for EBI across 2 studies with quantitative data.

Outcome data across 4 study arm–timepoint observations
SD
Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial
2025Exploratory
Psilocybin-assisted psychotherapy(experimental)17———
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression
2025Secondary
Low dose(experimental)1————
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression
2025Secondary
Medium dose(experimental)1————
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression
2025Secondary
High dose(experimental)1————

Papers Using EBI

Open Accessindividual

Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial

An open‑label pilot trial of two 25 mg psilocybin sessions with preparatory and integration psychotherapy for treatment‑resistant depression produced a clinically meaningful reduction in self‑rated depressive symptoms at three weeks (Hedges’ g = −1.27) that was maintained at 20 weeks, although individual responses varied (two sustained responders, three relapses, two non‑responders). Exploratory analyses linked pre‑dosing mindset, spiritual experiences and perceptual shifts to outcome trajectories, with adverse events consistent with prior studies and no serious adverse events.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Meikle, S., Carter, O., Liknaitzky, P., Johansen, L., Iyer, R., Strauss, N., Williams, M., Castle, D., Rossell, S. L., Ids, O.
Paywallindividual

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression

This re-analysis of the COMPASS Phase IIb trial (n=233) investigates the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcomes in treatment-resistant depression. Participants received a single dose of 25, 10, or 1 mg of psilocybin (COMP360) with psychological support. Higher doses produced stronger psychedelic effects, and reductions in depression (MADRS scores) at Week 3 correlated most strongly with dimensions of Oceanic Boundlessness (r = −0.508), Visual Restructuralization (r = −0.516), and Emotional Breakthrough Inventory (r = −0.637). Findings suggest the quality and intensity of psychedelic experiences mediate therapeutic outcomes and support dose-response mechanisms.

Published
Journal
Journal of Affective Disorders
Authors
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Carhart-Harris, R., Chai-Rees, J., Croal, M., Debattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Kirlic, N., Licht, R. W., Marwood, L., Meyer, T. D., Mistry, S., Nowakowska, A., Páleníček, T., Repantis, D., Schoevers, R. A., Simmons, H., Somers, M., Teoh, E., Tsai, J., Wahba, M., Williams, S., Young, A. H., Young, M. B., Zisook, S., Malievskaia, E.

Quick Facts

Full Name
Emotional Breakthrough Inventory
Domain
Mystical Experience
Papers Indexed
2
Score Range
6–30
Interpretation
Higher = better
Unit
points
All Measures